{"transactions":[{"id":745889,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40407,"kind":"person","name":"McGuire Daniel Patrick","position":1,"cik":"0002138590","reported_name":"McGuire Daniel Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GC and Secretary"}}],"security":"Common Stock","published_at":"2026-06-08T20:39:52.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying an RSU award.  The RSU vests in four (4) equal annual installments with the first annual vest taking place on June 4, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day that occurs on or after the day when the RSUs vest."}],"balance_after":109982,"source":{"system":"sec-edgar","filing":"0001193125-26-261871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526261871/ownership.xml","form_type":"4"}},{"id":745890,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:23:12.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":164950,"source":{"system":"sec-edgar","filing":"0001193125-26-261811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526261811/ownership.xml","form_type":"4"}},{"id":745887,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40410,"kind":"person","name":"Duncan Charles Cliff","position":1,"cik":"0002130896","reported_name":"Duncan Charles Cliff","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:21:51.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":98701,"source":{"system":"sec-edgar","filing":"0001193125-26-261806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526261806/ownership.xml","form_type":"4"}},{"id":745995,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:20:35.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":219054,"source":{"system":"sec-edgar","filing":"0001193125-26-261800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000119312526261800/ownership.xml","form_type":"4"}},{"id":745888,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:19:01.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027 provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":160667,"source":{"system":"sec-edgar","filing":"0001193125-26-261790","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526261790/ownership.xml","form_type":"4"}},{"id":746482,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:17:44.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":135069,"source":{"system":"sec-edgar","filing":"0001193125-26-261782","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000119312526261782/ownership.xml","form_type":"4"}},{"id":745886,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:26.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":112846,"source":{"system":"sec-edgar","filing":"0001193125-26-261768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526261768/ownership.xml","form_type":"4"}},{"id":769683,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T20:49:38.000Z","date":"2026-05-18","kind":"gift","planned":false,"acquired":false,"shares":25836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a gift to a charitable organization."}],"balance_after":71246,"source":{"system":"sec-edgar","filing":"0001802653-26-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000180265326000003/ownership.xml","form_type":"4"}},{"id":800772,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40410,"kind":"person","name":"Duncan Charles Cliff","position":1,"cik":"0002130896","reported_name":"Duncan Charles Cliff","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-24T20:36:42.000Z","date":"2026-04-22","kind":"grant","planned":false,"acquired":true,"shares":57101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on April 22, 2027, provided the Reporting Person has provided continuous service to the Issuer through each annual vesting date."}],"balance_after":57101,"source":{"system":"sec-edgar","filing":"0002130896-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000213089626000008/ownership.xml","form_type":"4"}},{"id":861683,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2026-03-04T23:54:11.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":42434,"price":8.2659,"value":350755.2006,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":377450,"source":{"system":"sec-edgar","filing":"0001748392-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000174839226000002/ownership.xml","form_type":"4"}},{"id":860977,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:52:29.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":30800,"price":8.2659,"value":254589.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":333469,"source":{"system":"sec-edgar","filing":"0001785888-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000178588826000002/ownership.xml","form_type":"4"}},{"id":860976,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2026-03-04T23:51:51.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":156235,"price":8.1734,"value":1276971.149,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.08 to $8.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":2704496,"source":{"system":"sec-edgar","filing":"0001355537-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000135553726000002/ownership.xml","form_type":"4"}},{"id":861762,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2026-03-04T18:53:14.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":42442,"price":8.2659,"value":350821.3278,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":411380,"source":{"system":"sec-edgar","filing":"0001806596-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000180659626000002/ownership.xml","form_type":"4"}},{"id":861636,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2026-03-04T18:51:11.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":42431,"price":8.2659,"value":350730.4029,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":494197,"source":{"system":"sec-edgar","filing":"0001702031-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000170203126000002/ownership.xml","form_type":"4"}},{"id":885355,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T21:28:24.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":8.03,"value":240900.0,"ownership":{"direct":true},"balance_after":93469,"source":{"system":"sec-edgar","filing":"0001193125-26-067185","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000119312526067185/ownership.xml","form_type":"4"}},{"id":892881,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2026-02-19T22:53:58.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\").  The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":364269,"source":{"system":"sec-edgar","filing":"0001193125-26-059792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526059792/ownership.xml","form_type":"4"}},{"id":893478,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2026-02-19T22:50:27.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\").  The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":419884,"source":{"system":"sec-edgar","filing":"0001193125-26-059781","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000119312526059781/ownership.xml","form_type":"4"}},{"id":892882,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2026-02-19T22:46:39.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":525000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\").  The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":2860731,"source":{"system":"sec-edgar","filing":"0001193125-26-059770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000119312526059770/ownership.xml","form_type":"4"}},{"id":893413,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2026-02-19T17:51:59.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\").  The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":536628,"source":{"system":"sec-edgar","filing":"0001193125-26-059784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000119312526059784/ownership.xml","form_type":"4"}},{"id":893513,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2026-02-19T17:48:34.000Z","date":"2026-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\").  The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.  Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":453822,"source":{"system":"sec-edgar","filing":"0001193125-26-059778","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000119312526059778/ownership.xml","form_type":"4"}},{"id":1071203,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-08-08T20:05:18.000Z","date":"2025-08-07","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.15,"value":41500.0,"ownership":{"direct":true},"balance_after":2335731,"source":{"system":"sec-edgar","filing":"0000950170-25-105819","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025105819/ownership.xml","form_type":"4"}},{"id":1109525,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T01:10:04.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":7000,"price":4.59,"value":32130.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":97082,"source":{"system":"sec-edgar","filing":"0000950170-25-087025","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025087025/ownership.xml","form_type":"4"}},{"id":1117535,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:36:16.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":59225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":104082,"source":{"system":"sec-edgar","filing":"0000950170-25-083890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025083890/ownership.xml","form_type":"4"}},{"id":1117534,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:35:49.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":59225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":123350,"source":{"system":"sec-edgar","filing":"0000950170-25-083889","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025083889/ownership.xml","form_type":"4"}},{"id":1117679,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:35:30.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":59225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":177454,"source":{"system":"sec-edgar","filing":"0000950170-25-083888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000095017025083888/ownership.xml","form_type":"4"}},{"id":1118266,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:34:48.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":59225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":123469,"source":{"system":"sec-edgar","filing":"0000950170-25-083885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000095017025083885/ownership.xml","form_type":"4"}},{"id":1117533,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:34:19.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":59225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":119067,"source":{"system":"sec-edgar","filing":"0000950170-25-083884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025083884/ownership.xml","form_type":"4"}},{"id":1138793,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-05-22T01:23:00.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":481,"price":4.39,"value":2111.59,"ownership":{"direct":true},"balance_after":2325731,"source":{"system":"sec-edgar","filing":"0000950170-25-076012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025076012/ownership.xml","form_type":"4"}},{"id":1138792,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-05-22T01:23:00.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":9519,"price":4.4,"value":41883.6,"ownership":{"direct":true},"balance_after":2325250,"source":{"system":"sec-edgar","filing":"0000950170-25-076012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025076012/ownership.xml","form_type":"4"}},{"id":1142130,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-05-19T21:13:38.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":4.2236,"value":84472.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.22 to $4.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":2315731,"source":{"system":"sec-edgar","filing":"0000950170-25-074565","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025074565/ownership.xml","form_type":"4"}},{"id":1219222,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-06T22:53:21.000Z","date":"2025-03-06","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.01,"value":25050.0,"ownership":{"direct":true},"balance_after":2295731,"source":{"system":"sec-edgar","filing":"0000950170-25-034966","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025034966/ownership.xml","form_type":"4"}},{"id":1219221,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-06T22:53:21.000Z","date":"2025-03-06","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.02,"value":25100.0,"ownership":{"direct":true},"balance_after":2290731,"source":{"system":"sec-edgar","filing":"0000950170-25-034966","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025034966/ownership.xml","form_type":"4"}},{"id":1221893,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-05T22:19:35.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.03,"value":25150.0,"ownership":{"direct":true},"balance_after":2285731,"source":{"system":"sec-edgar","filing":"0000950170-25-033845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025033845/ownership.xml","form_type":"4"}},{"id":1221892,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-05T22:19:35.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5.01,"value":25050.0,"ownership":{"direct":true},"balance_after":2280731,"source":{"system":"sec-edgar","filing":"0000950170-25-033845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025033845/ownership.xml","form_type":"4"}},{"id":1227147,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:46:48.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":15520,"price":4.76,"value":73875.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs."}],"balance_after":239269,"source":{"system":"sec-edgar","filing":"0000950170-25-032285","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025032285/ownership.xml","form_type":"4"}},{"id":1227145,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-04T21:45:52.000Z","date":"2025-03-03","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.705,"value":47050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":2275731,"source":{"system":"sec-edgar","filing":"0000950170-25-032276","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025032276/ownership.xml","form_type":"4"}},{"id":1227144,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-03-04T21:45:52.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":95999,"price":4.76,"value":456955.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs."}],"balance_after":2265731,"source":{"system":"sec-edgar","filing":"0000950170-25-032276","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025032276/ownership.xml","form_type":"4"}},{"id":1228880,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2025-03-04T21:44:58.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":26941,"price":4.76,"value":128239.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs."}],"balance_after":294884,"source":{"system":"sec-edgar","filing":"0000950170-25-032270","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000095017025032270/ownership.xml","form_type":"4"}},{"id":1228706,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2025-03-04T16:46:20.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":26941,"price":4.76,"value":128239.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs."}],"balance_after":411628,"source":{"system":"sec-edgar","filing":"0000950170-25-032281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000095017025032281/ownership.xml","form_type":"4"}},{"id":1229058,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2025-03-04T16:45:27.000Z","date":"2025-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":26941,"price":4.76,"value":128239.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs."}],"balance_after":328822,"source":{"system":"sec-edgar","filing":"0000950170-25-032273","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017025032273/ownership.xml","form_type":"4"}},{"id":1238088,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-28T22:30:11.000Z","date":"2025-02-28","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.76,"value":47600.0,"ownership":{"direct":true},"balance_after":2361730,"source":{"system":"sec-edgar","filing":"0000950170-25-030176","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025030176/ownership.xml","form_type":"4"}},{"id":1240374,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-27T21:13:59.000Z","date":"2025-02-27","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.76,"value":47600.0,"ownership":{"direct":true},"balance_after":2351730,"source":{"system":"sec-edgar","filing":"0000950170-25-029059","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025029059/ownership.xml","form_type":"4"}},{"id":1242598,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-26T21:46:41.000Z","date":"2025-02-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.78,"value":23900.0,"ownership":{"direct":true},"balance_after":2341730,"source":{"system":"sec-edgar","filing":"0000950170-25-027860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025027860/ownership.xml","form_type":"4"}},{"id":1242597,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-26T21:46:41.000Z","date":"2025-02-26","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":4.75,"value":23750.0,"ownership":{"direct":true},"balance_after":2336730,"source":{"system":"sec-edgar","filing":"0000950170-25-027860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025027860/ownership.xml","form_type":"4"}},{"id":1245543,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-26T00:38:24.000Z","date":"2025-02-25","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":4.464,"value":44640.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.445 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":2331730,"source":{"system":"sec-edgar","filing":"0000950170-25-027056","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025027056/ownership.xml","form_type":"4"}},{"id":1249775,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2025-02-24T19:04:25.000Z","date":"2025-02-21","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":4.3894,"value":8778.8,"ownership":{"direct":true},"balance_after":355763,"source":{"system":"sec-edgar","filing":"0000950170-25-025914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017025025914/ownership.xml","form_type":"4"}},{"id":1255280,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2025-02-21T01:21:39.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":254789,"source":{"system":"sec-edgar","filing":"0000950170-25-024498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025024498/ownership.xml","form_type":"4"}},{"id":1255279,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2025-02-21T00:45:37.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":2321730,"source":{"system":"sec-edgar","filing":"0000950170-25-024489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017025024489/ownership.xml","form_type":"4"}},{"id":1255915,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2025-02-21T00:43:29.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":321825,"source":{"system":"sec-edgar","filing":"0000950170-25-024485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000095017025024485/ownership.xml","form_type":"4"}},{"id":1255952,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2025-02-20T19:44:48.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":353763,"source":{"system":"sec-edgar","filing":"0000950170-25-024487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017025024487/ownership.xml","form_type":"4"}},{"id":1255820,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2025-02-20T19:44:07.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":438569,"source":{"system":"sec-edgar","filing":"0000950170-25-024486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000095017025024486/ownership.xml","form_type":"4"}},{"id":1361472,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-18T22:45:50.000Z","date":"2024-11-14","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":5.1726,"value":25863.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.195, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":44857,"source":{"system":"sec-edgar","filing":"0000950170-24-128115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024128115/ownership.xml","form_type":"4"}},{"id":1447180,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-07-29T17:24:41.000Z","date":"2024-07-29","kind":"sale","planned":false,"acquired":false,"shares":2251,"price":5.9203,"value":13326.5953,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."}],"balance_after":228763,"source":{"system":"sec-edgar","filing":"0000950170-24-087381","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017024087381/ownership.xml","form_type":"4"}},{"id":1501665,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-24T20:43:11.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":40202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":40202,"derivative":{"exercise_price":5.14,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":40202},"source":{"system":"sec-edgar","filing":"0000950170-24-064669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024064669/ownership.xml","form_type":"4"}},{"id":1501664,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T20:43:11.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":21887,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 22, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":64125,"source":{"system":"sec-edgar","filing":"0000950170-24-064669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024064669/ownership.xml","form_type":"4"}},{"id":1507386,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T20:55:09.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":37578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":37578,"derivative":{"exercise_price":5.48,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":37578},"source":{"system":"sec-edgar","filing":"0000950170-24-063022","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000095017024063022/ownership.xml","form_type":"4"}},{"id":1507385,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T20:55:09.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":20529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":64244,"source":{"system":"sec-edgar","filing":"0000950170-24-063022","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000095017024063022/ownership.xml","form_type":"4"}},{"id":1506978,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T20:53:30.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":37578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":37578,"derivative":{"exercise_price":5.48,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":37578},"source":{"system":"sec-edgar","filing":"0000950170-24-063019","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000095017024063019/ownership.xml","form_type":"4"}},{"id":1506977,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T20:53:30.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":20529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":118229,"source":{"system":"sec-edgar","filing":"0000950170-24-063019","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000095017024063019/ownership.xml","form_type":"4"}},{"id":1506844,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T20:53:14.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":37578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":37578,"derivative":{"exercise_price":5.48,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":37578},"source":{"system":"sec-edgar","filing":"0000950170-24-063017","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024063017/ownership.xml","form_type":"4"}},{"id":1506843,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T20:53:14.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":20529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":49857,"source":{"system":"sec-edgar","filing":"0000950170-24-063017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024063017/ownership.xml","form_type":"4"}},{"id":1506842,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-21T20:52:54.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":37578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":37578,"derivative":{"exercise_price":5.48,"expiration_date":"2034-05-16","underlying":"Common Stock","underlying_shares":37578},"source":{"system":"sec-edgar","filing":"0000950170-24-063015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024063015/ownership.xml","form_type":"4"}},{"id":1506841,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T20:52:54.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":20529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":59842,"source":{"system":"sec-edgar","filing":"0000950170-24-063015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024063015/ownership.xml","form_type":"4"}},{"id":1591802,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2024-03-06T21:50:29.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":8941,"price":4.1825,"value":37395.7325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.175 to $4.1901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":196825,"source":{"system":"sec-edgar","filing":"0000950170-24-027266","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000095017024027266/ownership.xml","form_type":"4"}},{"id":1591801,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2024-03-06T21:50:29.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":8147,"price":4.4086,"value":35916.8642,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.405 to $4.412, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":205766,"source":{"system":"sec-edgar","filing":"0000950170-24-027266","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000095017024027266/ownership.xml","form_type":"4"}},{"id":1591006,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2024-03-06T21:48:50.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":9229,"price":4.2074,"value":38830.0946,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.2027 to $4.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":129789,"source":{"system":"sec-edgar","filing":"0000950170-24-027259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024027259/ownership.xml","form_type":"4"}},{"id":1591005,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2024-03-06T21:48:50.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":7498,"price":4.4133,"value":33090.9234,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.4402, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":139018,"source":{"system":"sec-edgar","filing":"0000950170-24-027259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024027259/ownership.xml","form_type":"4"}},{"id":1591004,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-03-06T21:47:54.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":24288,"price":4.1285,"value":100273.008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":1871730,"source":{"system":"sec-edgar","filing":"0000950170-24-027256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024027256/ownership.xml","form_type":"4"}},{"id":1591003,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-03-06T21:47:54.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":30884,"price":4.2438,"value":131065.5192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.22 to $4.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1896018,"source":{"system":"sec-edgar","filing":"0000950170-24-027256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024027256/ownership.xml","form_type":"4"}},{"id":1591921,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-03-06T16:46:58.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":8902,"price":4.2025,"value":37410.655,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":231014,"source":{"system":"sec-edgar","filing":"0000950170-24-027253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017024027253/ownership.xml","form_type":"4"}},{"id":1591920,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-03-06T16:46:58.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":5798,"price":4.4812,"value":25981.9976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":239916,"source":{"system":"sec-edgar","filing":"0000950170-24-027253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017024027253/ownership.xml","form_type":"4"}},{"id":1591757,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2024-03-06T16:46:00.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":8684,"price":4.1322,"value":35884.0248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.1306 to $4.1339, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":313569,"source":{"system":"sec-edgar","filing":"0000950170-24-027249","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000095017024027249/ownership.xml","form_type":"4"}},{"id":1591756,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2024-03-06T16:46:00.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":8727,"price":4.2964,"value":37494.6828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default \"same day sale\" provisions of the RSU agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.28 to $4.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":322253,"source":{"system":"sec-edgar","filing":"0000950170-24-027249","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000095017024027249/ownership.xml","form_type":"4"}},{"id":1629474,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2024-02-21T21:53:28.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":213913,"source":{"system":"sec-edgar","filing":"0000950170-24-018033","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000095017024018033/ownership.xml","form_type":"4"}},{"id":1628391,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2024-02-21T21:52:55.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":32700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":146516,"source":{"system":"sec-edgar","filing":"0000950170-24-018032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024018032/ownership.xml","form_type":"4"}},{"id":1628390,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62782,"kind":"person","name":"Polymeropoulos Mihael Hristos","position":1,"cik":"0001355537","reported_name":"Polymeropoulos Mihael Hristos","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"President and CEO","other_text":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2024-02-21T21:52:23.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":1926902,"source":{"system":"sec-edgar","filing":"0000950170-24-018030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000095017024018030/ownership.xml","form_type":"4"}},{"id":1629521,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2024-02-21T16:52:48.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":245714,"source":{"system":"sec-edgar","filing":"0000950170-24-018027","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000095017024018027/ownership.xml","form_type":"4"}},{"id":1629388,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62821,"kind":"person","name":"Birznieks Gunther","position":1,"cik":"0001702031","reported_name":"Birznieks Gunther","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Business Development"}}],"security":"Common Stock","published_at":"2024-02-21T16:50:46.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":330980,"source":{"system":"sec-edgar","filing":"0000950170-24-018024","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702031/000095017024018024/ownership.xml","form_type":"4"}},{"id":1798485,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2023-08-23T20:23:55.000Z","date":"2023-08-21","kind":"sale","planned":false,"acquired":false,"shares":3724,"price":5.84,"value":21748.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":113816,"source":{"system":"sec-edgar","filing":"0001209191-23-047056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123047056/doc4.xml","form_type":"4"}},{"id":1809619,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:36:31.000Z","date":"2023-08-10","kind":"sale","planned":false,"acquired":false,"shares":6500,"price":6.0537,"value":39349.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.0952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":29328,"source":{"system":"sec-edgar","filing":"0001209191-23-045447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123045447/doc4.xml","form_type":"4"}},{"id":1819322,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-08-01T16:30:54.000Z","date":"2023-07-28","kind":"sale","planned":false,"acquired":false,"shares":1800,"price":6.305,"value":11349.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":120714,"source":{"system":"sec-edgar","filing":"0001209191-23-043990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000120919123043990/doc4.xml","form_type":"4"}},{"id":1819321,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-08-01T16:30:54.000Z","date":"2023-07-28","kind":"sale","planned":false,"acquired":false,"shares":412,"price":6.3,"value":2595.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":122514,"source":{"system":"sec-edgar","filing":"0001209191-23-043990","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000120919123043990/doc4.xml","form_type":"4"}},{"id":1849691,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62833,"kind":"person","name":"Moran Kevin Patrick","position":1,"cik":"0001806596","reported_name":"Moran Kevin Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Treasurer"}}],"security":"Common Stock","published_at":"2023-06-20T16:34:42.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":16000,"price":6.2944,"value":100710.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.23 to $6.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":122926,"source":{"system":"sec-edgar","filing":"0001209191-23-038417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806596/000120919123038417/doc4.xml","form_type":"4"}},{"id":1854417,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2023-06-15T20:20:35.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":14600,"price":6.5585,"value":95754.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.5986, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4."}],"balance_after":88913,"source":{"system":"sec-edgar","filing":"0001209191-23-037326","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000120919123037326/doc4.xml","form_type":"4"}},{"id":1858477,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:20:15.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":33960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":33960,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":33960},"source":{"system":"sec-edgar","filing":"0001209191-23-036289","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036289/doc4.xml","form_type":"4"}},{"id":1858476,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40411,"kind":"person","name":"Ward Anne Sempowski","position":1,"cik":"0001790117","reported_name":"Ward Anne Sempowski","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:20:15.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":39313,"source":{"system":"sec-edgar","filing":"0001209191-23-036289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036289/doc4.xml","form_type":"4"}},{"id":1858475,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:19:37.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":33960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":33960,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":33960},"source":{"system":"sec-edgar","filing":"0001209191-23-036285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036285/doc4.xml","form_type":"4"}},{"id":1858474,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40409,"kind":"person","name":"Mitchell Stephen Ray","position":1,"cik":"0001802653","reported_name":"Mitchell Stephen Ray","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:19:37.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":35828,"source":{"system":"sec-edgar","filing":"0001209191-23-036285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036285/doc4.xml","form_type":"4"}},{"id":1859182,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:19:01.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":33960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":33960,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":33960},"source":{"system":"sec-edgar","filing":"0001209191-23-036282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000120919123036282/doc4.xml","form_type":"4"}},{"id":1859181,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:19:01.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":43715,"source":{"system":"sec-edgar","filing":"0001209191-23-036282","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000120919123036282/doc4.xml","form_type":"4"}},{"id":1858559,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:18:16.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":33960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":33960,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":33960},"source":{"system":"sec-edgar","filing":"0001209191-23-036280","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000120919123036280/doc4.xml","form_type":"4"}},{"id":1858558,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40435,"kind":"person","name":"DUGAN RICHARD W","position":1,"cik":"0001263499","reported_name":"DUGAN RICHARD W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:18:16.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":97700,"source":{"system":"sec-edgar","filing":"0001209191-23-036280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1263499/000120919123036280/doc4.xml","form_type":"4"}},{"id":1858473,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:17:38.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":33960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":33960,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":33960},"source":{"system":"sec-edgar","filing":"0001209191-23-036275","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036275/doc4.xml","form_type":"4"}},{"id":1858472,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40412,"kind":"person","name":"Chrousos Phaedra","position":1,"cik":"0001774518","reported_name":"Chrousos Phaedra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:17:38.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":17307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date."}],"balance_after":42238,"source":{"system":"sec-edgar","filing":"0001209191-23-036275","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123036275/doc4.xml","form_type":"4"}},{"id":1947696,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-03-17T20:50:20.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":51276,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 25% of the underlying shares on March 15, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date."}],"balance_after":51276,"derivative":{"exercise_price":6.39,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":51276},"source":{"system":"sec-edgar","filing":"0001209191-23-019714","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000120919123019714/doc4.xml","form_type":"4"}},{"id":1947695,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":40568,"kind":"person","name":"Honore Tage","position":1,"cik":"0001967946","reported_name":"Honore Tage","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-17T20:50:20.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":26408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 15, 2024, provided the Reporting Person has provided continuous service through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest."}],"balance_after":26408,"source":{"system":"sec-edgar","filing":"0001209191-23-019714","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967946/000120919123019714/doc4.xml","form_type":"4"}},{"id":1969235,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2023-03-06T23:26:41.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":8301,"price":6.2507,"value":51887.0607,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.22 to $6.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":103513,"source":{"system":"sec-edgar","filing":"0001209191-23-016464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000120919123016464/doc4.xml","form_type":"4"}},{"id":1969234,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":52615,"kind":"person","name":"Williams Timothy","position":1,"cik":"0001748392","reported_name":"Williams Timothy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2023-03-06T23:26:41.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":8437,"price":6.2445,"value":52684.8465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2327 to $6.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":111814,"source":{"system":"sec-edgar","filing":"0001209191-23-016464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748392/000120919123016464/doc4.xml","form_type":"4"}},{"id":1968565,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2023-03-06T23:26:12.000Z","date":"2023-03-03","kind":"sale","acquired":false,"shares":4113,"price":6.32,"value":25994.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."}],"balance_after":117540,"source":{"system":"sec-edgar","filing":"0001209191-23-016463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123016463/doc4.xml","form_type":"4"}},{"id":1968564,"issuer":{"id":5861,"kind":"organization","name":"Vanda Pharmaceuticals Inc."},"owners":[{"id":62783,"kind":"person","name":"Wijkstrom Joakim","position":1,"cik":"0001785888","reported_name":"Wijkstrom Joakim","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Marketing Officer"}}],"security":"Common Stock","published_at":"2023-03-06T23:26:12.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":7720,"price":6.2335,"value":48122.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2201 to $6.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":121653,"source":{"system":"sec-edgar","filing":"0001209191-23-016463","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1347178/000120919123016463/doc4.xml","form_type":"4"}}],"next_cursor":"2023-03-06T23:26:12.000000Z,1968564"}